HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial.

ABSTRACT:

Purpose

We examined associations between tumor characteristics (human epidermal growth factor receptor 2 [HER2] protein expression, HER2 gene and chromosome 17 copy number, hormone receptor status) and disease-free survival (DFS) of patients in the N9831 adjuvant trastuzumab trial.

Patients and methods

All patients (N = 1,888) underwent chemotherapy with doxorubicin and cyclophosphamide, followed by weekly paclitaxel with or without concurrent trastuzumab. HER2 status was determined by immunohistochemistry (IHC) and fluorescent in situ hybridization (FISH) at a central laboratory, Mayo Clinic, Rochester, MN. Patients with conflicting local positive HER2 expression results but normal central laboratory testing were included in the analyses (n = 103).

Results

Patients w

SUBMITTER: Perez EA 

PROVIDER: S-EPMC2954132 | biostudies-literature | 2010 Oct

REPOSITORIES: biostudies-literature